AVOREN: Bevacizumab plus interferon extended OS in metastatic renal cell carcinoma - HemOncToday PDF Print
HemOncToday... showed that the combination of bevacizumab and interferon alfa-2a improved OS as first-line therapy in patients with metastatic renal cell carcinoma.

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.